# Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT07665515** · PHASE1 · RECRUITING · sponsor: **Epitopea Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Ovarian Cancer
- HGSOC
- HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** CryptiVax-1001

## Key facts

- **NCT ID:** NCT07665515
- **Lead sponsor:** Epitopea Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-03
- **Final completion:** 2029-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665515, "Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07665515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*